BioSpace News Archive

Sensorion announces that the first patient has been enrolled in its Phase 2a Proof of Concept clinical trial of SENS-401 in patients suffering from Cisplatin-Induced Ototoxicity.

Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea and related disorders, announced that it has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9, 2023, at 5:15 p.m. PT / 8:15 p.m. ET.

TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited.

Asensus Surgical, Inc. announced that Kitakyushu General Hospital, a hospital in the Kyushu area of Japan, entered into an agreement to lease and utilize a second Senhance® Surgical System, at the end of December 2022.

SpringWorks Therapeutics, Inc. announced that Saqib Islam, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 a.m. PT.

ALX Oncology Holdings Inc. announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 10:30 am PT at the Westin St. Francis in San Francisco.

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PST in San Francisco.

PolyPid Ltd announced the peer-reviewed publication of a post-hoc analysis from the previously-completed Phase 2 study of D-PLEX100 for the prevention of surgical site infections in abdominal surgery.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced the Company will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10, 2023, at 9:00 AM PST.